Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Investigating the Safety and Mechanistic Actions of Human Umbilical Cord Perivascular Cells as a New Fertility Preservation Treatment in Breast Cancer

FY 2024-25

Summary
More and more people are surviving breast cancer, the most common cancer in women, but chemotherapy is toxic to the reproductive system. Breast cancer survivors are vulnerable to infertility and a lower quality of life. Breast cancer patients need better fertility preservation treatments against chemotherapy toxicity as current treatments cannot do so and are not suited for all patients. Dr. Librach research team found that human umbilical cord (UC) cells can lessen chemotherapy toxicity in reproductive organs and slow tumour growth in animal models. To continue studying the use of UC cells in fertility preservation, I will first ensure the safety of UC cell treatments in breast cancer. UC cells should slow breast cancer growth by changing cancer cells environment and internal processes. To test UC cell treatments in breast cancer, I will use two models of three-dimensional (3D) mini-tumours made from breast cancer patients tumours: one with three cancer cell types and another with one cancer cell type. Mini-tumours will receive three forms of UC cell treatment and changes in their growth, appearance, and behaviour will be measured. Findings will be confirmed by treating UC cells to mice with breast cancer tumours to better understand how human patients might respond to UC cell therapy. To our knowledge, we are the first to use 3D mini-tumour models to study UC cell therapy in breast cancer. These mini-tumours should better represent patient tumours when compared to existing two-dimensional cancer cell models and further inform scientists of UC cell therapy application in breast cancer. Seeing how UC cells impact cancer growth is crucial for developing a better fertility preservation therapy for all cancer patients receiving chemotherapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530219
Name
Yao Yue Ying
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Safety and Mechanistic Actions of Human Umbilical Cord Perivascular Cells as a New Fertility Preservation Treatment in Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer Organoid; Cell Therapy; Chemotherapy Gonadotoxicity; Fertility Preservation; Human Umbilical Cord Mesenchymal Stromal Cells; Infertility; Oncofertility; Scrna Sequencing; Tumour Microenvironment
Abstract
More and more people are surviving breast cancer, the most common cancer in women, but chemotherapy is toxic to the reproductive system. Breast cancer survivors are vulnerable to infertility and a lower quality of life. Breast cancer patients need better fertility preservation treatments against chemotherapy toxicity as current treatments cannot do so and are not suited for all patients. Dr. Librach research team found that human umbilical cord (UC) cells can lessen chemotherapy toxicity in reproductive organs and slow tumour growth in animal models. To continue studying the use of UC cells in fertility preservation, I will first ensure the safety of UC cell treatments in breast cancer. UC cells should slow breast cancer growth by changing cancer cells environment and internal processes. To test UC cell treatments in breast cancer, I will use two models of three-dimensional (3D) mini-tumours made from breast cancer patients tumours: one with three cancer cell types and another with one cancer cell type. Mini-tumours will receive three forms of UC cell treatment and changes in their growth, appearance, and behaviour will be measured. Findings will be confirmed by treating UC cells to mice with breast cancer tumours to better understand how human patients might respond to UC cell therapy. To our knowledge, we are the first to use 3D mini-tumour models to study UC cell therapy in breast cancer. These mini-tumours should better represent patient tumours when compared to existing two-dimensional cancer cell models and further inform scientists of UC cell therapy application in breast cancer. Seeing how UC cells impact cancer growth is crucial for developing a better fertility preservation therapy for all cancer patients receiving chemotherapy.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yao, Yue Ying
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~